Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis

William E. Dager, Jeff H. King, Jennifer M. Branch, Stacey L. Chow, Ruby E. Ferrer, Sandy Pak, Patti Y. Togioka, Richard H White

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

BACKGROUND: The low-molecular-weight heparins (LMWHs) have been shown to be effective in the outpatient treatment of deep vein thrombosis (DVT). Data regarding outpatient use of any LMWH in pulmonary embolism (PE) or tinzaparin in DVT while transitioning therapy to a vitamin K antagonist are limited. OBJECTIVE: To determine the safety and efficacy of tinzaparin in patients with either DVT or PE being transitioned to warfarin during LMWH therapy in the outpatient setting. METHODS: All patients who were treated with at least one outpatient dose of tinzaparin for venous thromboembolism (VTE) were identified. Charts of all patients followed within the University of California Davis healthcare system were reviewed. The incidence of bleeding and recurrent thromboembolism over a minimum of the first 4 weeks to a maximum of 12 weeks after initiating anticoagulation was assessed. RESULTS: A total of 178 patients with acute VTE were treated with tinzaparin, and outcomes could be determined in 140 cases. Forty-seven percent of these patients had objectively documented PE. Only one (0.7%) case of recurrent VTE was observed. Major bleeding was documented in 5 (3.6%) and minor bleeding in 8 (5.8%) patients. Two bleeding events, both major, occurred during tinzaparin therapy. CONCLUSIONS: Outpatient use of tinzaparin during transition to warfarin therapy in the treatment of VTE, including PE, appears to be feasible in patients who are judged candidates for home therapy.

Original languageEnglish (US)
Pages (from-to)1182-1187
Number of pages6
JournalAnnals of Pharmacotherapy
Volume39
Issue number7-8
DOIs
StatePublished - Jul 2005

Fingerprint

Pulmonary Embolism
Venous Thrombosis
Outpatients
Venous Thromboembolism
Low Molecular Weight Heparin
Hemorrhage
Warfarin
Therapeutics
Vitamin K
Thromboembolism
tinzaparin
Delivery of Health Care
Safety
Incidence

Keywords

  • Deep vein thrombosis
  • Low-molecular-weight heparin
  • Outpatient treatment
  • Pulmonary embolism
  • Tinzaparin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Dager, W. E., King, J. H., Branch, J. M., Chow, S. L., Ferrer, R. E., Pak, S., ... White, R. H. (2005). Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis. Annals of Pharmacotherapy, 39(7-8), 1182-1187. https://doi.org/10.1345/aph.1E677

Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis. / Dager, William E.; King, Jeff H.; Branch, Jennifer M.; Chow, Stacey L.; Ferrer, Ruby E.; Pak, Sandy; Togioka, Patti Y.; White, Richard H.

In: Annals of Pharmacotherapy, Vol. 39, No. 7-8, 07.2005, p. 1182-1187.

Research output: Contribution to journalArticle

Dager, WE, King, JH, Branch, JM, Chow, SL, Ferrer, RE, Pak, S, Togioka, PY & White, RH 2005, 'Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis', Annals of Pharmacotherapy, vol. 39, no. 7-8, pp. 1182-1187. https://doi.org/10.1345/aph.1E677
Dager WE, King JH, Branch JM, Chow SL, Ferrer RE, Pak S et al. Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis. Annals of Pharmacotherapy. 2005 Jul;39(7-8):1182-1187. https://doi.org/10.1345/aph.1E677
Dager, William E. ; King, Jeff H. ; Branch, Jennifer M. ; Chow, Stacey L. ; Ferrer, Ruby E. ; Pak, Sandy ; Togioka, Patti Y. ; White, Richard H. / Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis. In: Annals of Pharmacotherapy. 2005 ; Vol. 39, No. 7-8. pp. 1182-1187.
@article{8adf9854deac44b9bbaab7d8dff42245,
title = "Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis",
abstract = "BACKGROUND: The low-molecular-weight heparins (LMWHs) have been shown to be effective in the outpatient treatment of deep vein thrombosis (DVT). Data regarding outpatient use of any LMWH in pulmonary embolism (PE) or tinzaparin in DVT while transitioning therapy to a vitamin K antagonist are limited. OBJECTIVE: To determine the safety and efficacy of tinzaparin in patients with either DVT or PE being transitioned to warfarin during LMWH therapy in the outpatient setting. METHODS: All patients who were treated with at least one outpatient dose of tinzaparin for venous thromboembolism (VTE) were identified. Charts of all patients followed within the University of California Davis healthcare system were reviewed. The incidence of bleeding and recurrent thromboembolism over a minimum of the first 4 weeks to a maximum of 12 weeks after initiating anticoagulation was assessed. RESULTS: A total of 178 patients with acute VTE were treated with tinzaparin, and outcomes could be determined in 140 cases. Forty-seven percent of these patients had objectively documented PE. Only one (0.7{\%}) case of recurrent VTE was observed. Major bleeding was documented in 5 (3.6{\%}) and minor bleeding in 8 (5.8{\%}) patients. Two bleeding events, both major, occurred during tinzaparin therapy. CONCLUSIONS: Outpatient use of tinzaparin during transition to warfarin therapy in the treatment of VTE, including PE, appears to be feasible in patients who are judged candidates for home therapy.",
keywords = "Deep vein thrombosis, Low-molecular-weight heparin, Outpatient treatment, Pulmonary embolism, Tinzaparin",
author = "Dager, {William E.} and King, {Jeff H.} and Branch, {Jennifer M.} and Chow, {Stacey L.} and Ferrer, {Ruby E.} and Sandy Pak and Togioka, {Patti Y.} and White, {Richard H}",
year = "2005",
month = "7",
doi = "10.1345/aph.1E677",
language = "English (US)",
volume = "39",
pages = "1182--1187",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "7-8",

}

TY - JOUR

T1 - Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis

AU - Dager, William E.

AU - King, Jeff H.

AU - Branch, Jennifer M.

AU - Chow, Stacey L.

AU - Ferrer, Ruby E.

AU - Pak, Sandy

AU - Togioka, Patti Y.

AU - White, Richard H

PY - 2005/7

Y1 - 2005/7

N2 - BACKGROUND: The low-molecular-weight heparins (LMWHs) have been shown to be effective in the outpatient treatment of deep vein thrombosis (DVT). Data regarding outpatient use of any LMWH in pulmonary embolism (PE) or tinzaparin in DVT while transitioning therapy to a vitamin K antagonist are limited. OBJECTIVE: To determine the safety and efficacy of tinzaparin in patients with either DVT or PE being transitioned to warfarin during LMWH therapy in the outpatient setting. METHODS: All patients who were treated with at least one outpatient dose of tinzaparin for venous thromboembolism (VTE) were identified. Charts of all patients followed within the University of California Davis healthcare system were reviewed. The incidence of bleeding and recurrent thromboembolism over a minimum of the first 4 weeks to a maximum of 12 weeks after initiating anticoagulation was assessed. RESULTS: A total of 178 patients with acute VTE were treated with tinzaparin, and outcomes could be determined in 140 cases. Forty-seven percent of these patients had objectively documented PE. Only one (0.7%) case of recurrent VTE was observed. Major bleeding was documented in 5 (3.6%) and minor bleeding in 8 (5.8%) patients. Two bleeding events, both major, occurred during tinzaparin therapy. CONCLUSIONS: Outpatient use of tinzaparin during transition to warfarin therapy in the treatment of VTE, including PE, appears to be feasible in patients who are judged candidates for home therapy.

AB - BACKGROUND: The low-molecular-weight heparins (LMWHs) have been shown to be effective in the outpatient treatment of deep vein thrombosis (DVT). Data regarding outpatient use of any LMWH in pulmonary embolism (PE) or tinzaparin in DVT while transitioning therapy to a vitamin K antagonist are limited. OBJECTIVE: To determine the safety and efficacy of tinzaparin in patients with either DVT or PE being transitioned to warfarin during LMWH therapy in the outpatient setting. METHODS: All patients who were treated with at least one outpatient dose of tinzaparin for venous thromboembolism (VTE) were identified. Charts of all patients followed within the University of California Davis healthcare system were reviewed. The incidence of bleeding and recurrent thromboembolism over a minimum of the first 4 weeks to a maximum of 12 weeks after initiating anticoagulation was assessed. RESULTS: A total of 178 patients with acute VTE were treated with tinzaparin, and outcomes could be determined in 140 cases. Forty-seven percent of these patients had objectively documented PE. Only one (0.7%) case of recurrent VTE was observed. Major bleeding was documented in 5 (3.6%) and minor bleeding in 8 (5.8%) patients. Two bleeding events, both major, occurred during tinzaparin therapy. CONCLUSIONS: Outpatient use of tinzaparin during transition to warfarin therapy in the treatment of VTE, including PE, appears to be feasible in patients who are judged candidates for home therapy.

KW - Deep vein thrombosis

KW - Low-molecular-weight heparin

KW - Outpatient treatment

KW - Pulmonary embolism

KW - Tinzaparin

UR - http://www.scopus.com/inward/record.url?scp=21744457102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21744457102&partnerID=8YFLogxK

U2 - 10.1345/aph.1E677

DO - 10.1345/aph.1E677

M3 - Article

C2 - 15956232

AN - SCOPUS:21744457102

VL - 39

SP - 1182

EP - 1187

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 7-8

ER -